Navigation Links
Biologics Research Promises to Bolster Future of Medicine
Date:3/11/2013

WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO)

The report includes biologics in human clinical trials or under review by the U.S. Food and Drug Administration such as:

  • 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma;
  • 134 vaccines for infectious diseases;
  • 71 medicines for autoimmune diseases including lupus, multiple sclerosis and rheumatoid arthritis;
  • 58 treatments for cardiovascular disease.

"These medicines reflect the cutting-edge research being conducted across the country by biopharmaceutical companies in order to provide new treatment options to patients," stated PhRMA President and CEO John J. Castellani .

The biologic medicines now in development make use of a range of new technologies to harness scientific progress.  Among the biologic medicines in development are:

  • A genetically-modified virus-based vaccine to treat melanoma;
  • A monoclonal antibody for the treatment of asthma;
  • An antisense therapy for the treatment of leukemia;
  • A recombinant fusion protein to treat type 2 diabetes.

"In order to realize the full potential of novel biologics to improve human health, it is essential to maintain public policy and regulatory environments to support the research and development that drives biomedical innovation," concluded Castellani.

The U.S. biopharmaceutical research sector supports nearly four million jobs across the economy, invests billions of dollars in research and development each year, and accounts for nearly 20 percent of all domestic R&D funded by U.S. businesses generating high-quality, high-wage jobs, powering the U.S. economy, and developing critical new treatments against our most costly and challenging diseases. 

The Biologic Medicines in Development report as well as an overview and other supplementary materials are available on PhRMA's website at http://phrma.org/research/new-medicines.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org 
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org   
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
2. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
3. Employers Becoming Savvier About Biologics and Specialty Drugs
4. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
5. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
6. Pinnacle Biologics acquires PDT laser technology
7. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
8. Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
9. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
10. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
11. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology:
(Date:5/3/2016)... Monica, CA (PRWEB) , ... May 03, 2016 , ... ... the highest quality medical providers to build the leading network of doctors and therapists ... Eric Nepomnaschy, D.C., founder of the distinguished Bay Chiropractic and Rehabilitation in ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution ... from a random library of sequences depending on their attraction for a target ... SELEX selection is commonly performed using filters, panning, or affinity chromatography separations. However, ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... ... leading innovative specialty pharmacies, will be represented at the 2016 Asembia Specialty ... Vegas. The Asembia Summit is the largest U.S. health care conference for the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):